Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) patients at risk for progression toward definite SSc

Arthritis Research & Therapy

Research

Chandra Mohan¹  Maurizio Marchini²  Chiara Bellocchi²  Marka Lyons³  Shervin Assassi³  Lorenzo Beretta⁴  Alessandro Santaniello⁴ 

[1] Department of Biomedical Engineering, University of Houston, Houston, TX, USA;Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy;Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy;Department of Internal Medicine – Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, USA;Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy;

关键词: Systemic sclerosis;    Proteomic;    Preclinical stage;    Disease progression;    Vasculopathy;   

DOI  :  10.1186/s13075-023-02989-w

 received in 2022-09-11, accepted in 2023-01-04,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThe study of molecular mechanisms characterizing disease progression may be relevant to get insights into systemic sclerosis (SSc) pathogenesis and to intercept patients at very early stage. We aimed at investigating the proteomic profile of preclinical systemic sclerosis (PreSSc) via a discovery/validation two-step approach.MethodsSOMAcan aptamer-based analysis was performed on a serum sample of 13 PreSSc (discovery cohort) according to 2001 LeRoy and Medsger criteria (characterized solely by Raynaud phenomenon plus a positive nailfold capillaroscopy and SSc-specific antibodies without any other sign of definite disease) and 8 healthy controls (HCs) age, gender, and ethnicity matched. Prospective data were available up to 4±0.6 years to determine the progression to definite SSc according to the EULAR/ACR 2013 classification criteria. In proteins with relative fluorescence units (RFU) > |1.5|-fold vs HCs values, univariate analysis was conducted via bootstrap aggregating models to determine the predicting accuracy (progression vs non-progression) of categorized baseline protein values. Gene Ontologies (GO terms) and Reactome terms of significant proteins at the adjusted 0.05 threshold were explored. Significant proteins from the discovery cohort were finally validated via ELISAs in an independent validation cohort of 50 PreSSc with clinical prospective data up to 5 years. Time-to-event analysis for interval-censored data was used to evaluate disease progression.ResultsIn the discovery cohort, 286 out of 1306 proteins analyzed via SomaScan, were differentially expressed versus HCs. Ten proteins were significantly associated with disease progression; analysis through GO and Reactome showed differentially enriched pathways involving angiogenesis, endothelial cell chemotaxis, and endothelial cell chemotaxis to fibroblast growth factor (FGF). In the validation cohort, endostatin (HR=10.23, CI95=2.2–47.59, p=0.003) was strongly associated with disease progression, as well as bFGF (HR=0.84, CI95=0.709-0.996, p=0.045) and PAF-AHβ (HR=0.372, CI95=0.171–0.809, p=0.013)ConclusionsA distinct protein profile characterized PreSSc from HCs and proteins associated with hypoxia, vasculopathy, and fibrosis regulation are linked with the progression from preclinical to definite SSc. These proteins, in particular endostatin, can be regarded both as markers of severity and molecules with pathogenetic significance as well as therapeutic targets.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

12888_2022_4443_Article_IEq4.gif

12888_2022_4443_Article_IEq2.gif

41116_2022_35_Article_IEq398.gif

41116_2022_35_Article_IEq397.gif

41116_2022_35_Article_IEq386.gif